Rhumbline Advisers Acquires 7,039 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

Rhumbline Advisers lifted its holdings in 10x Genomics, Inc. (NASDAQ:TXGFree Report) by 6.9% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 108,368 shares of the company’s stock after acquiring an additional 7,039 shares during the quarter. Rhumbline Advisers owned 0.09% of 10x Genomics worth $6,046,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. National Bank of Canada FI raised its holdings in 10x Genomics by 476.4% during the 1st quarter. National Bank of Canada FI now owns 611 shares of the company’s stock valued at $34,000 after buying an additional 505 shares during the last quarter. OLD Mission Capital LLC bought a new stake in 10x Genomics during the 4th quarter valued at $37,000. Harvest Fund Management Co. Ltd bought a new position in 10x Genomics in the 1st quarter worth $39,000. Atlas Capital Advisors LLC raised its holdings in 10x Genomics by 41.7% in the 2nd quarter. Atlas Capital Advisors LLC now owns 935 shares of the company’s stock worth $42,000 after purchasing an additional 275 shares in the last quarter. Finally, First Horizon Advisors Inc. raised its holdings in 10x Genomics by 33.2% in the 4th quarter. First Horizon Advisors Inc. now owns 1,625 shares of the company’s stock worth $59,000 after purchasing an additional 405 shares in the last quarter. 79.16% of the stock is currently owned by institutional investors.

Insider Activity at 10x Genomics

In other news, CFO Justin J. Mcanear sold 1,678 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $45.78, for a total transaction of $76,818.84. Following the sale, the chief financial officer now owns 98,784 shares of the company’s stock, valued at approximately $4,522,331.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Justin J. Mcanear sold 1,678 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $45.78, for a total transaction of $76,818.84. Following the sale, the chief financial officer now owns 98,784 shares of the company’s stock, valued at approximately $4,522,331.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Serge Saxonov sold 3,757 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The shares were sold at an average price of $45.78, for a total transaction of $171,995.46. Following the sale, the chief executive officer now directly owns 864,093 shares in the company, valued at approximately $39,558,177.54. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 82,044 shares of company stock valued at $4,697,096. 10.65% of the stock is owned by insiders.

10x Genomics Stock Performance

Shares of TXG stock opened at $52.17 on Thursday. 10x Genomics, Inc. has a one year low of $23.81 and a one year high of $63.57. The company’s 50-day moving average is $54.60 and its 200 day moving average is $53.18. The company has a market capitalization of $6.13 billion, a price-to-earnings ratio of -35.01 and a beta of 1.77.

10x Genomics (NASDAQ:TXGGet Free Report) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.14). 10x Genomics had a negative net margin of 30.31% and a negative return on equity of 21.69%. The firm had revenue of $146.82 million for the quarter, compared to analysts’ expectations of $139.97 million. During the same period last year, the company posted ($0.57) earnings per share. The business’s revenue for the quarter was up 28.1% compared to the same quarter last year. As a group, research analysts predict that 10x Genomics, Inc. will post -1.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on TXG shares. Barclays upped their price objective on shares of 10x Genomics from $65.00 to $66.00 and gave the stock an “overweight” rating in a report on Friday, August 4th. Morgan Stanley reaffirmed an “overweight” rating and issued a $65.00 target price on shares of 10x Genomics in a research report on Monday, August 7th. Finally, Citigroup upped their target price on shares of 10x Genomics from $65.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.64.

Read Our Latest Stock Report on 10x Genomics

10x Genomics Company Profile

(Free Report)

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Featured Stories

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.